Platelet inhibitor therapy: Current perspectives and emerging novel agents: Introduction - 08/08/11
Doi : 10.1016/j.ahj.2008.06.002
Dominick J. Angiolillo, MD, PhD, FACC, FESC a, ⁎ 
, Eric R. Bates, MD, FACC b
, Eric R. Bates, MD, FACC b a Division of Cardiology, University of Florida College of Medicine-Jacksonville, Jacksonville, FL
b Division of Cardiology, University of Michigan, Ann Arbor, MI
⁎Reprint requests: Dominick J. Angiolillo, MD, PhD, FACC, FESC, Division of Cardiology, University of Florida-Shands Jacksonville, 655 West 8th St, Jacksonville, FL 32209.
Résumé |
Antiplatelet therapy plays a key role in preventing atherothrombotic complications in patients with acute coronary syndromes and/or undergoing percutaneous coronary interventions. Despite such clinical benefit, currently available agents may present limitations. Several novel antiplatelet medications are currently under advanced clinical testing. Results from ongoing clinical studies will determine the efficacy and safety of these novel agents compared to those currently available.
Le texte complet de cet article est disponible en PDF.| Conflicts of Interest: Dominick J. Angiolillo, MD, PhD, FACC, FESC has declared the following conflicts of interest: Honoraria/Lectures: Bristol Myers Squibb (New York, NY); Sanofi-Aventis (Bridgewater, J); Eli Lilly and Company (Indianapolis, IN); Daiichi Sankyo, Inc (Parsippany, NJ). Honoraria/Advisory board: Bristol Myers Squibb; Sanofi-Aventis; Eli Lilly Co; Daiichi Sankyo, Inc.; The Medicines Company (Parsippany, NJ); Portola (San Francisco, CA); Novartis (East Hanover, NJ). Research Grants: GlaxoSmithKline (Brentford, London, United Kingdom); Otsuka (Tokyo, Japan). Eric R. Bates, MD, FACC has declared the following conflicts of interest: Honoraria/Lectures: Sanofi-Aventis; Hoffmann-La Roche (Nutley, NJ). Honoraria/Advisory board: Eli Lilly Co; The Medicines Company; Daiichi Sankyo, Inc.; Medicure Pharma (Winnipeg, Manitoba, Canada). Research Grants: Eli Lilly and Company. |
© 2008
Mosby, Inc. Tous droits réservés.
Vol 156 - N° 2S
P. 1S-2S - août 2008 Retour au numéro
Article précédent
- Table of Contents
- Current antiplatelet therapies: Benefits and limitations
- Dominick J. Angiolillo, Luis A. Guzman, Theodore A. Bass
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?